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The cutaneous lymphocyte-associated antigen defines
T lymphocytes with cutaneous tropism under
inflammatory conditions. Bacterial infections parti-
cipate in cutaneous inflammations, such as atopic
dermatitis or psoriasis. Bacterial superantigens, such
as staphylococcal enterotoxin B, can activate peri-
pheral blood mononuclear cells to induce effector
T cells bearing the T cell skin homing receptor
cutaneous lymphocyte-associated antigen via
enhancement of interleukin-12 production. We have
identified and characterized the anti-inflammatory
effects of different phosphodiesterase inhibitors on
this system. Our data indicate that the selective type
4 phosphodiesterase inhibitor rolipram inhibits the
Staphylococcal enterotoxin B-mediated generation
of cutaneous lymphocyte-associated antigen positive
Leukocytes extravasate into tissue by a multistep processinvolving different adhesion receptors, endothelial cellligands, and chemoattractants (Butcher and Picker,1996). T lymphocytes are present in the cellular infiltra-tion observed in chronic inflammation of different
tissues and their traffic to particular tissues is regulated by the
expression of specific T cell homing receptors (Butcher and Picker,
1996). Thus, interaction between circulating homing receptor-
bearing T lymphocytes with ligands expressed by endothelium is
essential in the multistep process of extravasation. There are three
well characterized T lymphocyte homing receptors: L-selectin,
α4β7 integrin and the CLA antigen. L-selectin mediates extravasa-
tion of T lymphocytes to high endothelial venules in lymph nodes
by interaction with carbohydrate ligands found on peripheral lymph
node addressins (Hemmerich et al, 1994). The α4β7 integrin is
found on T lymphocytes with nonrespiratory mucosal tropism, and
endothelial binding is through interaction with the MAdCAM-1
molecule (Berlin et al, 1993). Finally, the CLA antigen is a
carbohydrate modification of the P-selectin glycoprotein ligand-1
(PSGL-1) (Fuhlbrigge et al, 1997), which is preferentially expressed
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CD3F cells from peripheral blood mononuclear
cells by reducing interleukin-12 production in a
concentration-dependent manner. Conversely, type 3
phosphodiesterase or type 5 phosphodiesterase select-
ive inhibitors were not effective. The rolipram
inhibitory effect was on interleukin-12 production,
as exogenously added interleukin-12 could revert
rolipram suppression. These results suggest that
selective type 4 phosphodiesterase inhibition may
have beneficial effects on T cell mediated skin
inflammatory processes characterized by the presence
of bacterial infections, that are thought to exacerbate
ongoing skin inflammation. Key words: cutaneous
lymphocyte-associated antigen/cyclic adenosine monophos-
phate/interleukin-12/phosphodiesterase 4. J Invest Dermatol
113:82–86, 1999
by memory T cells present in cutaneous inflammatory sites (Picker
et al, 1990). CLA1 cells are also present in peripheral blood
mononuclear cells (PBMC) making 7–15% of the CD31 subset
(Picker et al, 1990). E-selectin is a ligand for CLA and it is
found on activated endothelial cells and mediates transendothelial
migration of CLA1 T cells (Picker et al, 1991) (Santamaria Babi
et al, 1995a) and murine CD41 T cells into inflamed skin (Tietz
et al, 1998). In a hu-SCID mouse model grafted with human skin
and human T cells it has been shown that CLA1 T cells migrate
to human skin in vivo (Kunstfeld et al, 1997). CLA1 T cells are
related to specific immune responses in the skin because these cells
preferentially respond to skin-associated antigens and their cytokine
secretion reflects the cytokine pattern found in cutaneous inflamed
lesions (Santamaria Babi et al, 1995b). Moreover, the CLA antigen
can be found in both Th1 and Th2 T cells (Teraki and Picker,
1997). Of all the cytokines analyzed, interleukin 12 (IL-12) has
been shown to be the most potent CLA inducing factor for T cells
undergoing activation (Leung et al, 1995). As bacterial superantigens,
which are very frequently found in skin inflammation, are potent
inducers of IL-12 they may influence cutaneous inflammation by
generating increased numbers of skin infiltrating T lymphocytes
(Leung, 1995).
Cyclic adenosine monophosphate (cAMP) has been shown to
modulate inflammatory and immunologic processes (Bourne et al,
1974). Phosphodiesterase (PDE) inhibitors increase intracellular
cAMP by blocking cAMP conversion to 59AMP. Of the nine PDE
isozyme families that have been currently identified (Torphy, 1998),
type 4 phosphodiesterase (PDE 4) is the most abundant PDE
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isozyme in inflammatory cells (Torphy and Undem, 1991). We
have studied whether PDE 4 selective inhibitors may be useful as
inhibitors of the superantigen Staphylococcal enterotoxin B (SEB)-
mediated IL-12 production and skin-homing T cell induction. Our
data indicate that cAMP elevating agents and in particular PDE4
inhibitors significantly inhibit CLA1 T cell generation by decreasing
SEB-induced IL-12 production.
MATERIAL AND METHODS
Antibodies and reagents The HECA-452 monoclonal antibody and
rat immunoglobulin M were from Pharmingen (San Diego, CA). Anti-L-
selectin conjugated to fluorescein isothiocyanate (FITC) and both mouse
immunoglobulin G2b-FITC and immunoglobulin G1 isotype controls
were from Serotec (Kidlington, U.K.). Anti-α4β7 monoclonal antibody
(Act-1) was kindly provided by Dr. S. Shaw (National Cancer Institute,
MA). Anti-CD3 conjugated to Phycoerythrin (PE) was from Becton
Dickinson (San Jose, CA). Anti-CD14 conjugated to PE, normal mouse
serum, goat-anti-mouse conjugated to FITC, N-2-O-dibutyryl-cAMP
(DbcAMP) and PGE2 were from Sigma (St. Louis, MO). Goat-antirat
conjugated to FITC was from Immunotech (Marseilles, France). Rolipram
[4-(39-cyclopentyloxy-49-methoxy-phenyl)-2-pyrrolidone] was synthe-
sized by our medical chemistry department. Siguazodan and Zaprinast were
a generous gift from SmithKline Beecham and Rhoˆne-Poulenc Rorer,
respectively.
Cell isolation and culture Human PBMC were isolated from venous
blood from healthy donors by density gradient centrifugation over Ficoll-
Paque, from Pharmacia (Uppsala, Sweden). PBMC were then washed
three times in phosphate-buffered saline from Biowhittaker (Verviers,
Belgium) supplemented with 2% fetal bovine serum (Gibco, Paisley, U.K.)
and resuspended in RPMI-1640 cell culture medium containing 10% fetal
bovine serum, L-glutamine (2 mM), penicillin (100 U per ml) and
streptomycin (100 µg per ml) all from Gibco. PBMC cells were stimulated
with SEB (Sigma) as described (Leung et al, 1995). Briefly, PBMC at
1.2 3 106 per ml were cultured in 48 well plates (Costar, Cambridge,
MA) with SEB at a previously titrated optimal concentration of 0.1 µg
per ml for 3 d at 37°C and 5% CO2. Lymphocytes were preincubated
with compounds [rolipram, zaprinast, siguazodan, prostaglandin (PG) E2
and DbcAMP] dissolved in dimethylsulfoxide or medium for 15 min prior
to the addition of SEB. The concentrations of siguazodan and zaprinast
used were above the IC50 for PDE 3 and PDE 5, respectively. No vehicle
effect was observed for the maximal dimethylsulfoxide concentrations used
in our assays (0.005%). To measure IL-12 levels, cell supernatants were
taken after 48 h culture and stored at –80°C until analyzed. The quantitation
of IL-12 was done using the Quantikine Immunoassay for IL-12 from
R&D Systems (Minneapolis, MN). In some experiments, exogenous human
IL-12 (Pharmingen) was added simultaneously with SEB or medium.
Cell staining and flow cytometric analysis Four-parameter analysis
was performed on a FACSCALIBUR flow cytometer (Becton Dickinson)
installed with a power-pack equipped with an argon laser of 488 nm
wavelength. Fluorescence 1 was measured using a 530 nm band pass filter,
fluorescence 2 with a band pass filter of 585 nm and fluorescence 3 with
a band pass filter of 650 nm. Typically, for immunofluorescence analysis,
5 3 105 cells were sequentially stained with primary nonconjugated
monoclonal antibody, goat-anti-rat conjugated to FITC or goat-anti-mouse
conjugated to FITC, 2% normal mouse serum and anti-CD3 conjugated
to PE. Stained cells were fixed in 2% paraformaldehyde in phosphate-
buffered saline and stored at 4°C until analyzed. Specific staining was
determined for each marker using appropriate isotype control antibodies.
Cells were analyzed using the Cellquest software from Becton Dickinson.
At day 0 analysis was performed gating only viable small lymphocytes.
Analysis of SEB-activated populations at day 3 was performed gating small
and T cell blast populations.
Data analysis Results are expressed as mean 6 SEM. Percentage
inhibition of the increase in CLA1CD31 cells by the various treatments
was calculated as follows: 100 – [(Treatment-Basal)/(SEB-Basal) 3 100].
Basal being the percentage of CLA1CD31 at the time of blood extraction,
SEB the percentage after 3 d of culture and Treatment the percentage after
3 d of culture in the presence of the different compounds tested. Assay
conditions were run in duplicate for each independent assay. Data were
analyzed using Student’s t test (one tail)
RESULTS
SEB preferentially induces the CLA antigen on 3 d activated
T lymphocytes Surface expression of CLA, L-selectin, and α4β7
integrin was measured on freshly isolated PBMC (day 0) and after
3 d of culture in the presence of 0.1 µg per ml SEB. As shown in
Fig 1 for a representative experiment, after 72 h culture with
SEB there is higher increase in the percentage of CLA1CD31
lymphocytes (Fig 1B) than for L-selectin1CD31 (Fig 1D) or
α4β71CD31 cells (Fig 1F) compared with their respective basal
levels at day 0 (Fig 1A, C, E). The percentages obtained are shown
in the upper right side of the quadrants. A significant increase for
CLA1CD31 cells related to the other two homing populations
after SEB activation was found in three independent experiments
giving the following fold increases from basal values: CLA1CD31
(3.5 6 0.09), L-selectin1CD31 (0.63 6 0.26, p , 0.01) and
α4β71CD31 (1.6 6 0.038, p , 0.01).
cAMP elevating agents inhibit SEB-mediated induction of
CLAFCD3F cells To check the effect of agents known to act
through the elevation of cAMP on the SEB-mediated CLA1CD31
induction, PGE2, DbcAMP, or rolipram were added to the cultures
15 min prior to SEB stimulation. All three compounds significantly
inhibited the generation of CLA1CD31 cells as is shown in Fig 2.
Furthermore, rolipram inhibited CLA1CD31 cells generation in a
concentration-dependent manner. The highest rolipram concentra-
tion tested (10 µM) showed a maximum inhibitory effect of 63.2%
(p , 0.001 respect to untreated samples). A significant inhibition
of 36.2% was also found for 1 µM rolipram (p , 0.005). Conversely,
neither siguazodan (a selective PDE 3 inhibitor) nor zaprinast
(a selective PDE 5 inhibitor) affected significantly the induction of
CLA1CD31 induced by SEB (Fig 3). To characterize further the
effect of rolipram on the induction of the CLA antigen we analyzed
whether rolipram had any effect on the expression of PSGL-1, the
protein backbone of CLA, in our experimental system. No effect
of rolipram was found on PSGL-1 expression for a dose range of
0.1–10 µM (data not shown).
Inhibition of CLAFCD3F T cell induction by rolipram is
mediated by the suppression of IL-12 production Generation
of CLA1 T cells after PBMC activation by SEB depends on the
production of IL-12 (Leung et al, 1995). In order to characterize
further the inhibitory effect of rolipram we harvested cell supernat-
ants from 48 h PBMC cultured with SEB with or without inhibitors
and IL-12 content was measured by enzyme-linked immunosorbent
assay. As shown in Fig 4, rolipram inhibited in a concentration-
dependent manner the SEB-mediated IL-12 production in four
independent experiments. Rolipram at 10 µM reduced the amount
of IL-12 detected to basal levels (p , 0.005). An 86% reduction
in the IL-12 production was also found at a rolipram concentration
of 1 µM (p , 0.01). Moreover, a parallel inhibition in the
percentage of CLA1 T cells was also observed in the same subjects
(data not shown).
Exogenous IL-12 reverts rolipram inhibition of SEB-
mediated CLAFCD3F induction In order to check whether
the effect of rolipram on the SEB-mediated CLA induction was
due to an inhibition of IL-12, this cytokine was exogenously added
together with SEB in a typical activation experiment. As it is shown
in Table I, IL-12 could significantly revert, in a concentration-
dependent manner, the effect of 10 µM rolipram in four
independent assays (p , 0.05).
DISCUSSION
Bacterial superantigens potently induce polyclonal T cell activation
and proliferation by simultaneously binding to certain Vβ elements
of the T cell receptor (TcR) and the β chain of the major
histocompatibility complex class II molecule present on the surface
of antigen-presenting cells (Marrack and Kappler, 1990). We have
focused in this work on the regulation by cAMP elevating agents
of the T cell activation induced by the SEB superantigen and, in
particular, on the SEB-mediated induction of the human T cell
skin homing receptor CLA from PBMC.
Our data indicate that these agents inhibit the SEB-mediated
84 SANTAMARIA ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Figure 1. SEB activation preferentially
induces the human skin-homing
receptor CLA. Flow cytometric analysis of
resting or 72 h SEB-activated PBMC.
Double staining to analyze CD31 cells
bearing one of the T lymphocyte homing
receptors (CLA, L-selectin or α4β7 integrin).
SEB-activated PBMC show a higher increase
in the number of CLA1CD31 (B) compared
with basal levels at day 0 (A) than for the
other two T lymphocyte homing
populations: L-selectin at day 0 and after
activation (C and D, respectively) and α4β7
at day 0 and after activation (E and F). Values
expressed in the upper right quadrant are the
percentage of double positive cells. This is a
representative experiment out of the three
independent assays.
increase of skin homing T lymphocytes and that this effect depends
on inhibition of IL-12 production.
Bacterial infections are involved in chronic cutaneous inflam-
matory diseases, such as psoriasis or atopic dermatitis (Leung et al,
1993; Leung, 1995). In these diseases, bacterial superantigens may
contribute to exacerbate the inflammatory status by modulating
cytokine production (Hemmerich et al, 1994), inducing liberation
of proinflammatory mediators and also by increasing the number
of CLA1 skin homing T cells (Leung et al, 1995). In addition,
SEB downregulates the expression of the mucosal T cell homing
receptor on human activated T lymphocytes (Herna´ndez-Caselles
et al, 1996) and, as shown in the present paper, does not affect
the expression of L-selectin. One of the cytokines induced by
superantigen activation of antigen-presenting cells is IL-12. It has
been shown that IL-12 is the most important cytokine involved in
the induction of the skin homing receptor CLA (Leung et al, 1995).
IL-12 is mainly produced by antigen-presenting cells, macrophages
and dendritic cells (Ma et al, 1997). As the PDE 4 isozyme is
present in monocytes we studied the effect of a PDE 4 inhibitor
on CLA1 T cell generation induced by SEB. Our data indicate
that rolipram dose-dependently inhibited the induction of CLA1
T cells up to a maximum of 60%, whereas PDE3 or PDE 5
inhibitors had no effect. This inhibition was likely to be due to
the reduction of IL-12 production observed in the presence of
rolipram. Additionally, IL-12 could revert the rolipram inhibitory
effect, further suggesting that PDE 4 inhibition of CLA1CD31
cell generation is mediated by IL-12 suppression.
It has been shown that cAMP enhancement by PGE2 or DbcAMP
inhibit IL-12 receptor expression and IL-12 responsiveness on
T cells (Wu et al, 1998). Those data indicate that in our system,
rolipram might also be affecting T cells. Such a possibility, however,
deserves further investigation.
It has recently been shown in animal models that rolipram can
reduce IL-12 production in a mouse model of collagen-induced
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Figure 2. cAMP elevating agents inhibit SEB-mediated generation
of skin-homing T cells. Effect of rolipram, PGE2, and DbcAMP in the
generation of CLA1CD31 lymphocytes from PBMC after SEB activation.
Compound preincubation for 15 min significantly inhibits the increase of
CLA1CD31 from basal levels. Results are expressed as the mean 6 SEM of
seven assays performed with lymphocytes from different donors (*p , 0.005;
**p , 0.001 vs. SEB-activated control samples).
Figure 3. PDE 4 but not PDE3 or PDE 5 inhibitors reduce SEB-
mediated CLA1CD31 induction. Comparison between rolipram (u),
zaprinast (r), and siguazodan (d) as inhibitors of CLA1CD31 cell
generation after SEB activation. Results are expressed as the mean 6 SEM
percentage of inhibition of CLA1CD31cell increase after SEB activation,
and were calculated from the values obtained in three independent
experiments.
arthritis (Ross et al, 1997) and of diabetes (Ling et al, 1998). Our
data indicate that PDE 4 inhibitors, through IL-12 inhibition, may
decrease the generation of new skin homing T lymphocytes and
therefore reduce some of the effects of superantigens in the lesions.
Interestingly, it has been shown that CLA1 T cell migration through
activated endothelium in vitro can be inhibited by blocking the CLA/
E-selectin interaction (Santamaria Babi et al, 1995a). Thus, PDE 4
inhibitors, by reducing the number of CLA1 T cells, may interfere
Figure 4. Rolipram inhibits SEB-mediated IL-12 production by
PBMC. Effect of rolipram in SEB-mediated PBMC production of IL-12.
Lymphocytes were cultured for 48 h and supernatants were analyzed by
enzyme-linked immunosorbent assay to detect human IL-12. Data from
four independent experiments including 6 SEM (*p , 0.005, **p , 0.01).
Table I. IL-12 reverts rolipram inhibition of SEB-mediated
CLAFCD3F cellsa
CLAFCD3Fb Percentage
% inhibition CLAFc
Basal 15.0 6 1.6
SEB 32.1 6 2.9
Rolipram 10 µM 24.5 6 3.1 44.1
Rolipram 10 µM 36.3 6 2.0* 224.5
1 10 ng per ml IL-12
Rolipram 10 µM 34.7 6 1.9* 215.2
1 1 ng per ml IL-12
Rolipram 10 µM 29.9 6 1.5* 12.8
1 0.1 ng per ml IL-12
Rolipram 10 µM 28.6 6 2.2 20.4
1 0.01 ng per ml IL-12
aExogenous recombinant human IL-12 at different concentrations (10–0.01 ng
per ml) was added together with rolipram in SEB-mediated induction of CLA1CD31
cells experiments.
bRepresent data from four different experiments (*p,0.05 compared with rolipram
10 µM).
cIndicates the average percentage inhibition of the four experiments.
in the recruitment of skin-homing T lymphocytes into the inflam-
matory sites.
Bacterial superantigens preferentially expand T cell subsets bearing
specific TcR Vβ segments (Hemmerich et al, 1994). In the case
of atopic dermatitis it has been shown that circulating CLA1 T
lymphocytes from children with atopic dermatitis and Staphylococcus
aureus infection express increased percentages of circulating
CLA1TcRVβ2 and TcRVβ 5.1. Interestingly, Vβ2 and Vβ5.1 seg-
ments are both recognized by SEB (Torres et al, 1998).
A similar restrictive association has also been described in circulat-
ing skin homing T lymphocytes from psoriatic patients.1 Moreover,
allergen-specific T cell lines derived from atopic dermatitis patients
1Davison S, Allen M, Harmer A, Vaugham R, Barker J: Evidence for
antigen restriction in peripheral blood lymphocytes in psoriasis. European
Society for Investigative Dermatology; Cologne, Germany. 999, 1998
(abstr.)
86 SANTAMARIA ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
display TcR associated with S. aureus derived superantigens, indicat-
ing that allergen may expands T cells which are susceptible to be
further activated by S. aureus.2 Taken together these data indicate
that skin infiltrating T lymphocytes in atopic dermatitis can be
influenced by bacterially derived products. The fact that PDE 4
inhibitors inhibit SEB activation and skin homing T cell generation
may be relevant in limiting the bacterial effects occurring in
cutaneous inflammatory disorders. It has been previously shown
that DbcAMP inhibits IL-12 production by human dendritic
cells (Panina-Bordignon et al, 1997) and that PGE2 inhibits
IL-12 production by lipopolysaccharide (LPS)-stimulated dendritic
cells (Rieser et al, 1997), IL-12 receptor expression, and IL-12
responsiveness (Wu et al, 1998). Moreover pentoxyfilline, a non-
selective PDE inhibitor suppresses IL-12 production by LPS-
stimulated human peripheral blood mononuclear cells (Moller,
1997). The inhibitory effect mediated by a selective PDE 4 inhibitor
on IL-12 production described in the present paper suggests that
this type of compound may also play an important part in the
treatment of allergic cutaneous inflammation.
Dendritic cells are the most powerful producers of IL-12,
particularly when CD40-bearing dendritic cells interact with CD40
ligand present on the T lymphocyte surface, even in the absence
of antigen recognition (Cella et al, 1996). Additionally, Th2
lymphocytes can induce IL-12 production by dendritic cells (Vezzio
et al, 1996) and in this way may upregulate the number of CLA1
Th2 lymphocytes. As CLA1 lymphocytes preferentially respond to
cutaneous allergens (Santamaria Babi et al, 1995b) and regulate
immunoglobulin E production through IL-4 and IL-13 (Santamaria
Babi et al, 1995b; Akdis et al, 1997) these cells play an important
part in the cutaneous allergic inflammation. Moreover, it has been
shown that IL-12 may contribute to established Th2 responses by
releasing IL-10 without inhibiting ongoing Th2 responses (Jeannin
et al, 1996). In this scenario, PDE 4 inhibitors may downregulate
ongoing IL-12-mediated allergic inflammation. On the other hand,
in chronic atopic dermatitis, a predominant Th1-type response
with an increase in IL-12 production in the lesions is found (Hamid
et al, 1996). In such situations PDE 4 inhibitory effects on IL-12
production may also be beneficial.
The clinical efficacy of a selective PDE 4 inhibitor which shows
anti-inflammatory effects in atopic dermatitis has been reported
(Hanifin et al, 1996). PDE 4 inhibitors, like rolipram, can inhibit
antigen-induced proliferation and cytokine (IL-2, IL-4, IL-5, and
interferon-γ) production (Essayan et al, 1994, 1997; Torphy, 1998).
In addition, our data suggest that this type of compound may also
be effective in controlling the superantigen-mediated chronic
inflammation found in cutaneous inflammatory disorders by
decreasing both the generation of new pathogenic effector skin
homing T lymphocytes and the IL-12-mediated exacerbation of
cutaneous inflammation.
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